Top SUS E&L Pitfalls—and How to Avoid Them



Published on 02/12/2025

Top SUS E&L Pitfalls—and How to Avoid Them

Understanding Extractables and Leachables (E&L) in Pharmaceutical Packaging

Extractables and leachables (E&L) are substances that can migrate from packaging or containment systems into pharmaceutical products. For pharmaceutical professionals, presenting a robust understanding of E&L is crucial to ensure product quality and compliance with regulatory standards such as those outlined by the FDA and the EMA. E&L studies identify potential contaminants from materials in contact with the drug product, particularly concerning single-use systems (SUS) such as filters, bags, and other container systems.

SUS is increasingly utilized in biopharmaceutical manufacturing for its benefits in reducing contamination risks and enabling flexible manufacturing processes. However, overlooked E&L risks can affect product safety, efficacy, and compliance. Therefore, a systematic approach to E&L risk assessment is imperative.

Identifying Common Pitfalls in E&L Studies

Conducting E&L studies requires careful consideration of various factors to avoid pitfalls that could jeopardize product approval. Below are the most common mistakes and how to prevent them:

  • Overlooking the Analytical Evaluation Threshold (AET). One common pitfall is failing to establish a scientifically justified AET during E&L studies. AET is pivotal in determining which leachables need further investigation based on their potential risk. Incorrect AET calculations may lead to overlooked contaminants.
  • Ignoring Dose-Based Threshold (DBT). Similarly, DBT is a crucial metric. It reflects the potential exposure to leachables and is often underestimated during assessments. Proper AET and DBT calculations contribute greatly to risk evaluation.
  • Inadequate characterization of materials. Failure to analyze the materials used in packaging, such as gamma-irradiated filters and components, can lead to missing significant E&L profiles. Proper characterization ensures that any potential extractables are identified early in the development stage.
  • Disregarding Container Closure Integrity (CCI). It is vital to assess the CCI of packaging systems post-sterilization and during storage conditions. A lack of thorough CCI testing can expose products to contamination.

Conducting a Comprehensive E&L Risk Assessment

A structured E&L risk assessment process is necessary to mitigate identified pitfalls. Here’s a step-by-step guide:

  1. Material Selection: Choose materials based on intended use and potential exposure to therapeutic products. Review supplier data for materials, hazards, and existing E&L profiles.
  2. Determine AET and DBT: Utilizing current research and guidance (e.g., PQRI guidelines), determine appropriate AET and DBT values specific to the dosage form. This quantification aids in establishing critical thresholds for leachables.
  3. Design the E&L Study: Select the extraction conditions that best mimic the intended product use scenarios. Consider variables such as temperature, time, and solvent selection that effectively extract potential leachables.
  4. Conduct Extractables Testing: Perform extractables studies using validated analytical methods. Employ techniques like gas chromatography tandem mass spectrometry (GC-MS) for accurate identification and quantification of extractables.
  5. Evaluate Leachables: Following initial testing, conduct leachables studies on the final product. Use the previously derived AET and DBT to guide the evaluation and risk assessment.
  6. Document Findings: Establish comprehensive reports that detail findings, methodologies, and risk assessments in accordance with cGMP practices. This documentation supports compliance with regulatory submission requirements.
  7. Continuous Monitoring: Implement a monitoring program post-launch to track and validate the packaging integrity and continued compliance with E&L standards.

Implementing Robust Container Closure Integrity (CCI) Practices

CContainer closure integrity (CCI) is an essential component of E&L studies. CCI ensures the sterility and safety of drug products and requires diligent methods and practices. Neglecting CCI can directly impact product quality. Here’s how to establish robust CCI practices:

  • Selection of Appropriate Test Methods: Utilize methodologies such as vacuum leak testing and non-destructive testing methodologies. According to USP guidelines, ensure verifiable methods align with the standards set forth in USP CCI.
  • Conduct Studies Under Realistic Conditions: Evaluate CCI robustness under the conditions the product will face throughout its lifecycle—considering transport, storage, and various environmental factors.
  • Integration with E&L Assessments: Combine CCI assessments with E&L studies ensuring that closures that exhibit weak integrity are investigated for potential leachables.
  • Consistent Training and Awareness: Educate personnel on the significance of CCI within E&L assessments. Training should encompass current guidelines and technologies available for testing.

Navigating Regulatory Requirements for E&L Studies

Regulatory bodies such as the FDA, EMA, and MHRA stipulate specific requirements for E&L studies in pharmaceuticals. Awareness of relevant compliance frameworks and guidelines is critical for successful submissions:

  • FDA Guidelines: The FDA insists on comprehensive E&L assessments for parenteral and biotechnology products. Reference the FDA’s guidance on container closure systems in their review indicating acceptable methodologies for assessment.
  • EU GMP Annex 1: This annex clearly outlines the necessity of E&L studies and mandates CCI testing for sterilized products. Ensure that any E&L submissions are in line with these directives to prevent regulatory challenges.
  • ICH Guidelines: The International Council for Harmonisation of Technical Requirements (ICH) provides comprehensive guidance on testing, quality control, and risk management practices to ensure global compliance.

Case Studies: Learning from E&L Failures

Analyzing real-world examples of E&L failures can provide invaluable lessons on the importance of thorough validation processes:

  • Case Study 1 – Contaminated Drug Product: A biopharmaceutical company experienced a costly recall due to leachables exceeding the AET from single-use filters. Investigation revealed inadequate extraction studies had been performed. The mistake was rectified by reassessing materials and conducting comprehensive E&L profiling.
  • Case Study 2 – Non-Compliance with CCI Requirements: A sterile product faced batch rejections due to compromised CCI during shipping. The root cause was identified as improper sealing methods during packaging. Revised sealing practices and enhanced testing resulted in improved compliance.

Best Practices for E&L and Packaging Qualification

To avoid E&L pitfalls, integrate best practices into the validation of single-use systems:

  • Develop Robust Protocols: Create rigorous validation protocols for each step of E&L assessments, focusing on comprehensive documentation, role definitions, and compliance checkpoints.
  • Ongoing Supplier Assessment: Maintain a proactive approach toward assessing suppliers and material quality. Regular audits and supplier evaluations help ensure that materials align with E&L requirements.
  • Engagement with Regulatory Authorities: Foster transparent communications with regulatory bodies. Prioritize alignment with current guidance and seek clarification on any ambiguous compliance areas.

Conclusion

Addressing E&L risks in pharmaceutical packaging is pivotal to ensuring the safety and efficacy of drug products. By employing a structured and thorough approach to E&L studies, enhancing CCI evaluation methods, and adhering to regulatory expectations, pharmaceutical professionals can avoid common pitfalls and contribute to the delivery of high-quality therapeutics. This not only supports compliance with cGMP but also underpins a robust risk management framework essential for successful market presence.